CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

PartnershiplacutamabPositive
AI Analysis

Summary

Sobi and Innate Pharma entered a strategic partnership to license lacutamab for T-cell lymphoma, enabling initiation of the TELLOMAK-3 confirmatory trial.

Clinical Trial Data

Importance:7/10
Sentiment:
0.60
licensingpartnershiponcologyT-cell lymphomalacutamabTELLOMAK-3
Related Companies

Read the original article

Published by PR Newswire Pharma on August 10, 2026 6:36 AM

Read Original